Central Nervous System Lymphoma Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Central Nervous System Lymphoma Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

August 16
08:15 2021
Central Nervous System Lymphoma Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
Central Nervous System Lymphoma Market

Central Nervous System Lymphoma, is a rare type of non-Hodgkin lymphoma (NHL) in which malignant cells from lymph tissue form in the brain or spinal cord or spread from other parts of the body to the brain or spinal cord.

When it is formed in the brain it is known as primary CNS lymphoma (PCNSL) and when it spreads from other parts of the body to the brain or spinal cord it is known as Secondary CNS lymphoma. Because the eye is so close to the brain, primary CNS lymphoma can also start in the eye. Both primary and secondary CNS lymphomas are rare diseases.

 

DelveInsight’s Central Nervous System Lymphoma Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Central Nervous System Lymphoma, historical and forecasted epidemiology as well as the Central Nervous System Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some key facts of Central Nervous System Lymphoma Market:

  • According to the Leukemia and Lymphoma Society, CNS Lymphoma is more common in men than women and the median age of diagnosis is 55, however the median age of AIDS-infected patients with primary CNS lymphoma is 35.
  • As per the study Mendez, Joe S., et al. titled “The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades.“ the cases of PCNSL were higher in people aged 70–79 years followed by 60–69 years , and 50–59 years.
  • As per Malik Ghannam et al., the PCNSL is rare, accounting for 2–6% of all primary brain neoplasms and 1–2% of all non-Hodgkin lymphomas, and it usually presents as a solitary lesion.
  • According to Grommes Christian et al., in recent years, a rising incidence has been recognized for PCNSL, particularly in patients older than 60 years, with an incidence rate of 0.5 per 100,000 per year.

 

Request for Sample Report: https://www.delveinsight.com/sample-request/central-nervous-system-lymphoma-market

 

Scope of Central Nervous System Lymphoma Market Report:

  • Central Nervous System Lymphoma market report covers a descriptive overview and comprehensive insight of the Central Nervous System Lymphoma epidemiology and Central Nervous System Lymphoma market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  • Central Nervous System Lymphoma market report provides insights on the current and emerging therapies.
  • Central Nervous System Lymphoma market report offers a global historical and forecasted market covering drug outreach in 7MM.
  • Central Nervous System Lymphoma market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Central Nervous System Lymphoma market.

 

Request for Sample Report: https://www.delveinsight.com/sample-request/central-nervous-system-lymphoma-market

 

Central Nervous System Lymphoma Companies covered:

  • Janssen
  • Eli Lilly
  • Bristol-Myers Squibb
  • Turning Point Therapeutics
  • Novartis
  • Celltrion
  • And Many Others

 

Central Nervous System Lymphoma Therapies are:

  • Imbruvica
  • Abemaciclib
  • Nivolumab
  • Repotrectinib
  • Tisagenlecleucel
  • Rixumab + Methotrexate followed by Rituximab + Cytarabine
  • And Many Others

 

Table of Contents:

1. Key Insights

2. Executive Summary of Central Nervous System Lymphoma

3. Competitive Intelligence Analysis for Central Nervous System Lymphoma

4. Central Nervous System Lymphoma: Market Overview at a Glance

5. Central Nervous System Lymphoma: Disease Background and Overview

5.1. Introduction

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Central Nervous System Lymphoma Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Central Nervous System Lymphoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Central Nervous System Lymphoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/central-nervous-system-lymphoma-market

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/central-nervous-system-lymphoma-market

Related Articles

Categories